Efficacy And Safety Of Nanoparticle Albumin-Bound Paclitaxel For Treating Metastatic Breast Cancer:A Meta-Analysis

Objective Systematic review nanoparticle albumin-bound paclitaxel (albumin-bound paclitaxel) for the treatment of metastatic breast cancer, the efficacy and safety, to provide the basis for clinical treatmentMethods Literature databases were searched for relevant randomized controlled trials (RCTs). Data on overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of adverse effects were meta-analyzed to yield pooled odds ratios (ORs) or hazard ratios (HRs) with 95% confidence intervals (CI). Using Comprehensive Meta-Analysis 2.0 (BIOSTAT, Englewood, NJ) to calculate 3 grade neutropenia incidence and 4 grade neutropenia incidenceResults The meta-analysis included six RCTs involving 1614 patients. Nab-paclitaxel was associated with significantly higher ORR than were control drug treatments[OR2.46,95% CI(1.92～3.14), P <0.00001]. It was also associated with higher PFS than were control drug treatments [HR0.83,95%CI(0.73～0.94), P=0.003]. However, OS was similar for nab-paclitaxel and control treatments [HR0.87,95%CI(0.71 ～1.05), P=0.14]. Analysis of the six studies showed that nab-paclitaxel was associated with significantly higher risk of grade 3 sensory neuropathy than were control drug treatments [OR1.82,95% CI(1.21～2.74), P=0.004]. Nab-paclitaxel group 3 grade neutropenia incidence [32.8%,95%CI (29.8～35.9%)],4 grade neutropenia incidence [6.9%,95%CI (5.3～9.1%)].Conclusion Nab-paclitaxel in the treatment of metastatic breast cancer have a higher overall response rate (ORR), progression-free survival (PFS), but overall survival (OS) has no significant difference, while the incidence of grade 3 sensory neurotoxicity also large. But still need more and higher-quality randomized controlled trials to further verification...